Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intrinsic Dosimetry for Radioembolization Utilizing PET-CT Imaging Data: A Prospective Registry Study

NCT02088775 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.

NCT NCT02088775
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02088775 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intrinsic Dosimetry for Radioembolization Utilizing PET-CT Imaging Data: A Prospective Registry Study
Lead sponsor
Fox Chase Cancer Center
Phase
Not applicable
Overall status
Completed
Start date
February 28, 2014
Completion date
July 30, 2021
Enrollment
44 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adult primary hepatocellular carcinoma, advanced adult primary liver cancer, metastatic extrahepatic bile duct cancer, recurrent adult primary liver cancer, recurrent extrahepatic bile duct cancer, stage d adult primary liver cancer (bclc), unspecified adult solid tumor, protocol specific